Otsu/Shiga, Japan – May 13, 2015 - Takara Bio Inc. announced that on May 12, 2015, it acquired “Accreditation of foreign cell processor” which allows companies to conduct specific processed cell manufacturing, according to the Act on the Safety of Regenerative Medicine, from Kinki Regional Bureau of Health and Welfare, Ministry of Health, Labour and Welfare. Following enforcement of the Act in November 2014, specific processed cell manufacturing, which had been allowed only for medical institutions, can be outsourced to companies. Thus, Takara Bio acquired accreditation of the foreign cell processor (valid from May 12, 2015 to May 11, 2020), for the Center for Gene and Cell Processing at Kusatsu office, Shiga. This acquisition of accreditation enables Takara Bio to provide medical institutions with contracted cell processing service. It has developed technologies including cell processing technique through clinical development of gene and cell therapies and provision of technical support for cancer immunotherapy. Now it can provide a seamless package of cell processing, safety tests and quality tests of cells, and expand earnings in bioindustry business.
